Anzeige
Mehr »
Sonntag, 15.02.2026 - Börsentäglich über 12.000 News
20 Mio. € Bewertung. Zwei zugelassene Psychedelika-Produkte. NASDAQ-Uplist in Arbeit.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
141 Leser
Artikel bewerten:
(0)

Imagene AI and Shaare Zedek Medical Center Form Strategic Data-AI Collaboration to Scale Oncology Research and Care

The collaboration combines Shaare Zedek's real-world data and clinical expertise with Imagene AI's Oncology Intelligence Suite to advance biomarker discovery and accelerate precision cancer care.

TEL AVIV, IL / ACCESS Newswire / October 29, 2025 / Imagene AI, a pioneer in multimodal foundation models for precision oncology, and Shaare Zedek Scientific, the innovation arm of Shaare Zedek Medical Center, today announced a strategic collaboration to advance cancer research and personalized care with multimodal AI and real-world data.

Imagene AI Oncology Intelligence Suite

Imagene AI Oncology Intelligence Suite

The collaboration brings together Shaare Zedek's real-world data, clinical research, and advanced digital infrastructure with Imagene AI's Cross-Modality Intelligence Engine and OI Suite platform. The partnership aims to accelerate biomarker discovery, enable multimodal translational research, and support more precise and timely treatment decisions.

"Our mission is to improve patient care through innovation," said Renana Ofan, CEO of Shaare Zedek Scientific, the innovation arm of Shaare Zedek Medical Center. "Partnering with Imagene AI allows us to integrate advanced intelligence tools directly into our research workflows, empowering our clinicians and scientists to accelerate discoveries and bring data-driven innovation closer to patients. Together, we are building the foundations for AI-powered oncology research that improves both understanding and outcomes

Shaare Zedek Scientific will provide Imagene AI access to de-identified multimodal, longitudinal data to enrich Imagene AI's proprietary real-world data lake. This will enrich Imagene AI's proprietary real-world data lake. Shaare Zedek's researchers and clinicians will gain access to OI Suite to independently analyze multimodal datasets, generate biomarker hypotheses, and develop predictive models across cancer types. The platform also enables users to explore explainable AI outputs such as region-level heatmaps and histological features in a secure, no-code environment.

"This collaboration strengthens our mission to transform oncology research through real-world data and AI," said Dean Bitan, Co-founder and CEO of Imagene AI. "Together with Shaare Zedek, we are expanding the frontiers of discovery, making multimodal intelligence accessible to researchers and bringing precision oncology closer to patients."

Real-world data is a critical foundation for advancing AI-powered oncology research. By continuously expanding its proprietary real-world data lake, Imagene AI is strengthening the infrastructure that supports multimodal discovery, biomarker development, and translational research across cancer types. The company recently launched the OI Suite Discovery Program, offering complimentary access for biopharma teams to accelerate discovery and precision oncology.

About Imagene AI
Imagene AI is a pioneer in multimodal foundation models for precision medicine, advancing translational research and clinical development. Our Cross-Modality Intelligence Engine, delivered through the OI Suite, integrates real-world data including histopathology images, multi-omic data, longitudinal clinical records to derive meaningful, biologically grounded insights, generate and validate biomarker hypotheses, and increase predictive power in low-data settings. We make every trial more responsive, every insight more actionable, and every patient journey more personalized. For more information, visit Imagene.com.

About Shaare Zedek Scientific
Shaare Zedek Scientific Ltd. (Mada'it) is the research and innovation arm of Shaare Zedek Medical Center, Jerusalem's fastest-growing major hospital. Mada'it bridges cutting-edge medical research with clinical excellence, partnering with leading health-tech companies to accelerate the development of transformative healthcare solutions. By harnessing the hospital's clinical expertise, advanced infrastructure, and diverse patient population, Mada'it translates early-stage research into impactful medical treatments. Our mission is to extend Shaare Zedek's legacy of care and discovery to benefit patients worldwide. For more information, visit madait.co.il.

Contact Information

Avital Rabani
VP of Marketing
media@imagene-ai.com

.

SOURCE: Imagene AI



View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/biotechnology/imagene-ai-and-shaare-zedek-medical-center-form-strategic-data-ai-collaboration-to-sc-1092663

© 2025 ACCESS Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.